Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
25 hedge funds and large institutions have $5.14M invested in Amplify Treatments, Testing and Advancements ETF in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
11% less funds holding
Funds holding: 28 → 25 (-3)
23% less capital invested
Capital invested by funds: $6.71M → $5.14M (-$1.57M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$493K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$66K |
| 3 |
LPL Financial
San Diego,
California
|
+$39.1K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$11.8K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$5.95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$1.09M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$39.5K |
| 3 |
APA
American Portfolios Advisors
Holbrook,
New York
|
-$31.6K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$28.8K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$27.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Koshinski Asset Management
Decatur,
Illinois
| – | -$17.2K | -629 | Closed |
|
27
Simplex Trading
Chicago,
Illinois
| – | -$9K | -333 | Closed |
|
|
TFP
28
Tilia Fiduciary Partners
Wilmington,
North Carolina
| – | -$5K | -183 | Closed |
|
|
BHWM
29
Beaird Harris Wealth Management
Dallas,
Texas
| – | -$1K | -46 | Closed |
|
GERM Hedge Fund Activity: Q2 2022 in Review
25 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q2 2022, worth a combined $5.14M — down 23% from $6.71M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of GERM and 2 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 7 added.
The largest buyer was Susquehanna International Group, adding an estimated $493K. The largest seller was Goldman Sachs, cutting an estimated $1.09M.
- 25 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q2 2022, down from 28 in Q1 2022.
- Funds reported $5.14M of Amplify Treatments, Testing and Advancements ETF stock for Q2 2022, down 23% quarter-over-quarter.
- 2 funds opened new Amplify Treatments, Testing and Advancements ETF positions in Q2 2022 and 5 closed out, a net change of -3 holders.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q2 2022 was Susquehanna International Group, an estimated $493K added.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q2 2022 was Goldman Sachs, an estimated $1.09M sold.
Based on aggregated 13F filings for Q2 2022.